Synfacts 2022; 18(12): 1366
DOI: 10.1055/s-0042-1753089
Innovative Drug Discovery and Development

Small Molecule Inhibitors of the YAP-TEAD Interaction

Contributor(s):
Antonia F. Stepan (Roche)
,
Danica A. Rankic (Pfizer)
Furet P. * et al. Novartis Institutes for BioMedical Research, Basel, Switzerland
The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition.

ChemMedChem 2022;
17: e202200303
DOI: 10.1002/cmdc.202200303.
 

Significance

Disruption of the YAP-TEAD protein–protein interaction (PPI) represents an opportunity to treat cancers associated with proliferation mediated by the Hippo signaling pathway. However, due to the extended and shallow surface that YAP and TEAD interact through, identification of efficient small-molecule inhibitors of the YAP-TEAD PPI has been challenging. Using virtual screening and structure-based drug design, Furet and co-workers have identified compound 2 which is a potent disruptor of the YAP-TEAD PPI both biochemically and in a cellular setting.


#

Comment

The single enantiomer dihydrobenzofuran present in intermediates A and B was installed through a key Mitsunobu reaction and salt resolution. Guided by structure, Furet and co-workers leveraged intermediates A and B to explore hydrophobic substitution at the 4-position of the dihydro­benzofuran scaffold through Suzuki coupling. ­Ultimately, compound 2 was synthesized in 47% yield via Suzuki coupling of compound B, followed by nitrile hydration, Boc deprotection and chroma­tographic separation from the undesired biaryl ­diastereomer 1.


#
#

Publication History

Article published online:
17 November 2022

© 2022. Thieme. All rights reserved

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany